So, you were right, Harry. Pharma isn't giving up on their investment.
I was hopeful this would help CCSVI research, but there's just no money in that.
1. A prospective, observational, single-blinded, longitudinal study of atalizumab effect on brain atrophy and disability in multiple sclerosis patients over 5 years. Agency: Biogen Idec, Inc.
2. Evolution of gray matter (GM) atrophy over 4 years in observational study of early interferon (IFN)β-1a intramuscular (I.M.) (Avonex® ) treatment in high risk subjects after clinically isolated syndrome (SET substudy). Agency: Biogen Idec, Inc.
3. Assessment of lesion activity analysis in the Avonex- Steroid-Azathioprine (ASA) study.
Agency: Biogen Idec, Inc.
Aim: To examine short- and long-term value of appearance of new active lesions in predicting extent of cortical and subcortical atrophy over 5 years in ASA study.
and Teva is looking at if GA affects iron deposition in deep GM.
4. A prospective, observational, single-blinded, longitudinal MRI study of effect of glatiramer acetate on iron deposition in patients with relapsing-remitting multiple sclerosis over 24 months.
Agency: Teva Pharmaceuticals, Inc.
Aim: To explore whether treatment with GA may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls. To investigate whether treatment with GA may decrease accumulation of iron in lesions, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months.